Lattice Capital Management LLC Buys Shares of 3,700 Insmed Incorporated (NASDAQ:INSM)

Lattice Capital Management LLC purchased a new position in shares of Insmed Incorporated (NASDAQ:INSM) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 3,700 shares of the biopharmaceutical company’s stock, valued at approximately $255,000. Insmed accounts for about 0.2% of Lattice Capital Management LLC’s portfolio, making the stock its 26th largest holding.

Other institutional investors and hedge funds have also recently modified their holdings of the company. V Square Quantitative Management LLC raised its stake in Insmed by 60.3% during the fourth quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the period. Spire Wealth Management acquired a new stake in shares of Insmed during the 4th quarter worth approximately $47,000. Venturi Wealth Management LLC purchased a new stake in shares of Insmed during the 4th quarter valued at approximately $86,000. Quantbot Technologies LP acquired a new position in Insmed in the third quarter valued at approximately $133,000. Finally, Blue Trust Inc. grew its position in Insmed by 2,348.8% in the third quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 1,879 shares during the period.

Wall Street Analysts Forecast Growth

INSM has been the topic of a number of research analyst reports. Truist Financial lifted their target price on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Wednesday. Wells Fargo & Company increased their target price on shares of Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Insmed in a research report on Friday. Finally, Guggenheim upped their price objective on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $91.00.

Insider Activity at Insmed

In other news, insider Martina M.D. Flammer sold 6,172 shares of the stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the completion of the sale, the insider now owns 101,549 shares in the company, valued at approximately $6,462,578.36. This trade represents a 5.73 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO William Lewis sold 2,978 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the transaction, the chief executive officer now directly owns 392,589 shares in the company, valued at $24,874,439.04. This trade represents a 0.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 532,207 shares of company stock worth $41,400,465. 4.60% of the stock is owned by insiders.

Insmed Price Performance

INSM opened at $81.06 on Friday. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $84.91. The company’s 50 day simple moving average is $74.29 and its 200 day simple moving average is $73.59. The stock has a market capitalization of $14.50 billion, a PE ratio of -14.61 and a beta of 1.11. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.15). The business had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. As a group, sell-side analysts expect that Insmed Incorporated will post -5.42 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.